Prognosis of screen-detected breast cancers: results of a population based study

BACKGROUND: The reduced mortality rate from breast carcinoma among women offered screening mammography is demonstrated after 15–20 years of follow-up. However, the assessment of 5-year overall and event-free survival could represent an earlier measure of the efficacy of mammography screening program (MSP). METHODS: All cases of breast cancer diagnosed in the Province of Modena between years 1996 and 2000 in women aged 50 to 69 years, were identified through the Modena Cancer Registry (MCR). Stage of disease and treatment information were obtained from clinical records. All the events occurring up to June 30, 2003 were retrieved by experienced monitors. Five-year overall and event-free survival were the principal end-points of the study. RESULTS: During a 5-year period, 587 primary breast cancers were detected by the MSP and 471 primary breast cancers were diagnosed out of the MSP. The screen-detected breast cancers were smaller, more likely node negative, with low histological grade, low proliferative activity and positive receptors status. Furthermore, the breast cancer diagnosed through the MSP more frequently received a conservative surgery. The 5-year survival rate was 94% in the screen-detected group, versus 84% in the other group (p = 0.0001). The rate of 5-year event-free survival was 89% and 75% for the MSP participants and not participants, respectively (p = 0.0001). CONCLUSIONS: Our data confirm a favourable outcome of screen-detected breast cancers in terms of five-year overall and event-free survival, which reflect the good quality assurance parameters of the MSP. Finally, a cancer registry should be implemented in every area covered by screening programs

Prognosis of screen-detected breast cancers: results of a population based study-2

<p><b>Copyright information:</b></p><p>Taken from "Prognosis of screen-detected breast cancers: results of a population based study"</p><p>BMC Cancer 2006;6():17-17.</p><p>Published online 23 Jan 2006</p><p>PMCID:PMC1413546.</p><p>Copyright © 2006 Cortesi et al; licensee BioMed Central Ltd.</p>ts and non-participants were equal to 98% and 96% (Log Rank = 0.76) respectively (a) and 93% and 89% (Log Rank = 1.57) respectively (b). [ = MSP participants; = MSP non-participants

Prognosis of screen-detected breast cancers: results of a population based study-0

<p><b>Copyright information:</b></p><p>Taken from "Prognosis of screen-detected breast cancers: results of a population based study"</p><p>BMC Cancer 2006;6():17-17.</p><p>Published online 23 Jan 2006</p><p>PMCID:PMC1413546.</p><p>Copyright © 2006 Cortesi et al; licensee BioMed Central Ltd.</p>ere equal to 89% and 75% respectively (Log Rank = 19.99). [ = MSP participants; = MSP non-participants

Prognosis of screen-detected breast cancers: results of a population based study-4

<p><b>Copyright information:</b></p><p>Taken from "Prognosis of screen-detected breast cancers: results of a population based study"</p><p>BMC Cancer 2006;6():17-17.</p><p>Published online 23 Jan 2006</p><p>PMCID:PMC1413546.</p><p>Copyright © 2006 Cortesi et al; licensee BioMed Central Ltd.</p>ts were equal to 87% and 73% respectively (Log Rank = 5.02). [ = MSP participants; = MSP non-participants

Prognosis of screen-detected breast cancers: results of a population based study-3

<p><b>Copyright information:</b></p><p>Taken from "Prognosis of screen-detected breast cancers: results of a population based study"</p><p>BMC Cancer 2006;6():17-17.</p><p>Published online 23 Jan 2006</p><p>PMCID:PMC1413546.</p><p>Copyright © 2006 Cortesi et al; licensee BioMed Central Ltd.</p>ts were equal to 95% and 91% respectively (Log Rank = 5.74). [ = MSP participants; = MSP non-participants

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study

We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies